Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 12/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31045799 | 0.83 | MTNR1A (0.43) | TRPV1MBOAT4 | |
| SCHEMBL3552064 | 0.82 | TRPV1 (0.43) | TRPV1MBOAT4PTGS1 | |
| SCHEMBL13136015 | 0.77 | MBOAT4 (0.46) | TRPV1L3MBTL1MBOAT4PTGS1PTGS2 | |
| SCHEMBL12993561 | 0.76 | MBOAT4 (0.44) | TRPV1MBOAT4 | |
| SCHEMBL23287266 | 0.75 | MBOAT4 (0.45) | TRPV1MBOAT4 | |
| SCHEMBL17986246 | 0.75 | MBOAT4 (0.45) | TRPV1NPSR1MBOAT4PTGS2 | |
| SCHEMBL13757105 | 0.75 | MBOAT4 (0.45) | TRPV1L3MBTL1MBOAT4PTGS2 | |
| SCHEMBL21503515 | 0.72 | MBOAT4 (0.41) | TRPV1MBOAT4 | |
| SCHEMBL2528780 | 0.72 | MBOAT4 (0.48) | TRPV1MBOAT4 | |
| SCHEMBL4472362 | 0.72 | MBOAT4 (0.45) | TRPV1L3MBTL1MBOAT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4680336-A1 | AMIDE DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF | Ventus Therapeutics U.S., Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| US-20260007684-A1 | AMIDE DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF | VENTUS THERAPEUTICS U S INC (US) | 2026-01-08 | — | — | US | disclosed |
| WO-2024196788-A1 | AMIDE DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF | VENTUS THERAPEUTICS U.S., INC. (US) | 2024-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260007684-A1 | AMIDE DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF | NOD1, NLRP3, NOD2 | TRPV1 527/4885TSHR 3171/4885NPSR1 1857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.